Matches in SemOpenAlex for { <https://semopenalex.org/work/W1982488045> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W1982488045 endingPage "20" @default.
- W1982488045 startingPage "15" @default.
- W1982488045 abstract "First-, second-, and third-line therapies for the treatment of metastatic colorectal cancer may influence choices for subsequent therapy. First-line treatment for metastatic colorectal cancer depends largely on combination chemotherapy regimens that have been proven to prolong survival, control disease progression, and improve quality of life, without excessive toxicity. Standard therapies include 5-fluorouracil, irinotecan, and oxaliplatin, but other combination therapies are currently under investigation. An upcoming area of study includes agents that target vascular endothelial growth factor and epidermal growth factor receptor. While doublet therapy is more active than 5-fluorouracil alone, triplet therapy is also emerging. Second-line therapy is dependent upon prior treatment, and second-line FOLFIRI or FOLFOX regimens that incorporate 5-fluorouracil, leucovorin, and either irinotecan or oxaliplatin, respectively, are still in question because of residual toxicities. After combination chemotherapy, a non–cross-resistant chemotherapy is the best choice. Second-line targeted therapy has been well-tolerated and active in several trials. Future developments will most likely occur in the areas of pharmacogenetics (eg, toxicity, age, comorbidities, patient choice, strategy of cure, palliation) and pharmacogenomics (eg, resistance/activity, gene expression) to produce individualized therapies for patients. The type of adjuvant treatment, genomic consideration, and genetic predisposition will be determining factors in the ideal protocol for first-line therapy." @default.
- W1982488045 created "2016-06-24" @default.
- W1982488045 creator A5012784092 @default.
- W1982488045 creator A5065620187 @default.
- W1982488045 date "2005-12-01" @default.
- W1982488045 modified "2023-10-16" @default.
- W1982488045 title "Metastatic Colorectal Cancer: First- and Second-Line Treatment in 2005" @default.
- W1982488045 cites W1958949331 @default.
- W1982488045 cites W2016726396 @default.
- W1982488045 cites W2051224942 @default.
- W1982488045 cites W2096122707 @default.
- W1982488045 cites W2112759697 @default.
- W1982488045 cites W2114857812 @default.
- W1982488045 cites W2121368761 @default.
- W1982488045 cites W2128403792 @default.
- W1982488045 cites W2128447158 @default.
- W1982488045 cites W2133399075 @default.
- W1982488045 cites W2142564546 @default.
- W1982488045 cites W2157416388 @default.
- W1982488045 cites W2157769714 @default.
- W1982488045 cites W2162313061 @default.
- W1982488045 cites W2314927739 @default.
- W1982488045 cites W2327611741 @default.
- W1982488045 doi "https://doi.org/10.1053/j.seminoncol.2005.07.020" @default.
- W1982488045 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16360007" @default.
- W1982488045 hasPublicationYear "2005" @default.
- W1982488045 type Work @default.
- W1982488045 sameAs 1982488045 @default.
- W1982488045 citedByCount "17" @default.
- W1982488045 countsByYear W19824880452014 @default.
- W1982488045 countsByYear W19824880452015 @default.
- W1982488045 countsByYear W19824880452016 @default.
- W1982488045 countsByYear W19824880452020 @default.
- W1982488045 crossrefType "journal-article" @default.
- W1982488045 hasAuthorship W1982488045A5012784092 @default.
- W1982488045 hasAuthorship W1982488045A5065620187 @default.
- W1982488045 hasConcept C121608353 @default.
- W1982488045 hasConcept C126322002 @default.
- W1982488045 hasConcept C143998085 @default.
- W1982488045 hasConcept C2776694085 @default.
- W1982488045 hasConcept C2776705615 @default.
- W1982488045 hasConcept C2777802072 @default.
- W1982488045 hasConcept C2778260052 @default.
- W1982488045 hasConcept C2779998722 @default.
- W1982488045 hasConcept C2780259306 @default.
- W1982488045 hasConcept C2780456651 @default.
- W1982488045 hasConcept C2780962732 @default.
- W1982488045 hasConcept C526805850 @default.
- W1982488045 hasConcept C71924100 @default.
- W1982488045 hasConceptScore W1982488045C121608353 @default.
- W1982488045 hasConceptScore W1982488045C126322002 @default.
- W1982488045 hasConceptScore W1982488045C143998085 @default.
- W1982488045 hasConceptScore W1982488045C2776694085 @default.
- W1982488045 hasConceptScore W1982488045C2776705615 @default.
- W1982488045 hasConceptScore W1982488045C2777802072 @default.
- W1982488045 hasConceptScore W1982488045C2778260052 @default.
- W1982488045 hasConceptScore W1982488045C2779998722 @default.
- W1982488045 hasConceptScore W1982488045C2780259306 @default.
- W1982488045 hasConceptScore W1982488045C2780456651 @default.
- W1982488045 hasConceptScore W1982488045C2780962732 @default.
- W1982488045 hasConceptScore W1982488045C526805850 @default.
- W1982488045 hasConceptScore W1982488045C71924100 @default.
- W1982488045 hasLocation W19824880451 @default.
- W1982488045 hasLocation W19824880452 @default.
- W1982488045 hasOpenAccess W1982488045 @default.
- W1982488045 hasPrimaryLocation W19824880451 @default.
- W1982488045 hasRelatedWork W167317102 @default.
- W1982488045 hasRelatedWork W1962954254 @default.
- W1982488045 hasRelatedWork W2037039278 @default.
- W1982488045 hasRelatedWork W2068448950 @default.
- W1982488045 hasRelatedWork W2091789348 @default.
- W1982488045 hasRelatedWork W2235788479 @default.
- W1982488045 hasRelatedWork W2415702816 @default.
- W1982488045 hasRelatedWork W2589622699 @default.
- W1982488045 hasRelatedWork W2809146871 @default.
- W1982488045 hasRelatedWork W3110357236 @default.
- W1982488045 hasVolume "32" @default.
- W1982488045 isParatext "false" @default.
- W1982488045 isRetracted "false" @default.
- W1982488045 magId "1982488045" @default.
- W1982488045 workType "article" @default.